Tarsus Pharmaceuticals Inc (TARS)
SG&A Expenses
$150.70M
Quarterly · Period ending: · USD
TARS SG&A Expenses
Latest reported$150.70Mperiod ending
Latest reported$150.70Mperiod ending
TARS Quarterly SG&A Expenses ($112.25K → $150.70M)
Quarterly SG&A Expenses
High-resolution chart · PNG
TARS sg&a expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expenses (USD) |
|---|---|
| 150,697,000 | |
| 136,429,000 | |
| 130,681,999 | |
| 108,633,000 | |
| 103,013,000 | |
| 84,995,000 | |
| 69,030,000 | |
| 57,910,000 | |
| 58,792,000 | |
| 51,578,000 | |
| 43,005,000 | |
| 30,324,000 | |
| 19,959,000 | |
| 14,841,000 | |
| 14,633,000 | |
| 11,783,000 | |
| 10,376,000 | |
| 7,946,000 | |
| 6,772,000 | |
| 6,671,000 | |
| 6,794,000 | |
| 5,160,000 | |
| 3,890,000 | |
| 2,150,000 | |
| 1,526,000 | |
| 606,000 | |
| 387,000 | |
| 214,000 | |
| 112,250 | |
| 112,250 |